AS900672-Enriched 10 microgram (mcg) + AS900672-Enriched 20 mcg + AS900672-Enriched 30 mcg + AS900672-Enriched 40 mcg + Follitropin alfa 75 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG)
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovulation Induction
Conditions
Ovulation Induction
Trial Timeline
Dec 1, 2007 → Mar 1, 2009
NCT ID
NCT00553514About AS900672-Enriched 10 microgram (mcg) + AS900672-Enriched 20 mcg + AS900672-Enriched 30 mcg + AS900672-Enriched 40 mcg + Follitropin alfa 75 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG)
AS900672-Enriched 10 microgram (mcg) + AS900672-Enriched 20 mcg + AS900672-Enriched 30 mcg + AS900672-Enriched 40 mcg + Follitropin alfa 75 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG) is a phase 2 stage product being developed by Merck for Ovulation Induction. The current trial status is terminated. This product is registered under clinical trial identifier NCT00553514. Target conditions include Ovulation Induction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00553514 | Phase 2 | Terminated |
Competing Products
13 competing products in Ovulation Induction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR7280 tablets | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Follitropin alpha (r-FSH) | Merck | Pre-clinical | 23 |
| Recombinant FSH (follitropin alpha) | Merck | Approved | 85 |
| MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha | Merck | Phase 3 | 77 |
| Lutropin alfa + Follitropin alfa | Merck | Approved | 85 |
| Orlistat Vs Metformin | Roche | Pre-clinical | 23 |
| Levonorgestrel + Ethinyl Estradiol | Pfizer | Phase 2 | 51 |
| EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L) | Bayer | Phase 2 | 49 |
| Myo-inositol + Clomiphene Citrate | Richter Gedeon | Approved | 82 |
| corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) + human Chorion Gonadotropin (hCG) + hCG Bolus injection | Organon | Phase 2 | 47 |
| usual administration of exogenous recombinant FSH | Organon | Pre-clinical | 18 |
| Follitropin beta | Organon | Pre-clinical | 18 |